The adenosine A 1 receptor (A1R) inhibits ␤-adrenergic-induced contractile effects (antiadrenergic action), and the adenosine A 2A receptor (A 2AR) both opposes the A1R action and enhances contractility in the heart. This study investigated the A 1R and A2AR function in ␤-adrenergic-stimulated, isolated wild-type and A 2AR knockout murine hearts. Constant flow and pressure perfused preparations were employed, and the maximal rate of left ventricular pressure (LVP) development (ϩdp/dt max) was used as an index of cardiac function. A 1R activation with 2-chloro-N 6 -cyclopentyladenosine (CCPA) resulted in a 27% reduction in contractile response to the ␤-adrenergic agonist isoproterenol (ISO). Stimulation of A2AR with 2-P(2-carboxyethyl)phenethyl-amino-5Ј-N-ethylcarboxyamidoadenosine (CGS-21680) attenuated this antiadrenergic effect, resulting in a partial (constant flow preparation) or complete (constant pressure preparation) restoration of the ISO contractile response. These effects of A2AR were absent in knockout hearts. Up to 63% of the A2AR influence was estimated to be mediated through its inhibition of the A1R antiadrenergic effect, with the remainder being the direct contractile effect. Further experiments examined the effects of A2AR activation and associated vasodilation with low-flow ischemia in the absence of ␤-adrenergic stimulation. A2AR activation reduced by 5% the depression of contractile function caused by the flow reduction and also increased contractile performance over a wide range of perfusion flows. This effect was prevented by the A2AR antagonist 4-
ADENOSINE PLAYS a role in modulating cardiac functions. In the well-oxygenated myocardium, intracellular levels of adenosine are low, but they rapidly increase in response to adrenergic stimulation or pathological conditions, such as ischemia and hypoxia (10, 11) . Four adenosine receptor subtypes have been identified and cloned (13) . The adenosine A 1 and A 2A receptors (A 1 R and A 2A R, respectively) are thought to be particularly important in the regulation of cardiac contractility (4, 7, 9, 19, 26) . A 2 R are also known to be responsible for coronary vasodilation, with A 2A R considered the main contributor to this effect (27, 31) . A 2B receptors are considered more important to fibroblast regulation (3) . The role of adenosine A 3 receptors is less certain, although they have been linked to preconditioning (24) and have recently been shown to activate PKB in newborn rat cardiomyocytes (14) . The A 1 R is known to exhibit an antiadrenergic action reducing the contractile responsiveness of the myocardium to adrenergic stimulation (1, 5, 6, 12) . A 2A R, on the other hand, appears to have a direct inotropic effect on the myocardium (4, 26, 34) by facilitating a greater response to adrenergic stimulation (19, 33) and an indirect effect by inhibiting the action of the A 1 R (28, 34) .
Both A 1 R and A 2A R are G protein-linked receptors coupled to G i and G s , respectively (13) . The effects of these receptors are thought to be mediated either through the modulation of adenylyl cyclase activity (4, 19) with subsequent activation of PKA (8, 13) or via activation of phosphatidylinositol 3-kinase with the subsequent activation of endothelial nitric oxide synthase (eNOS) (17, 32, 35) . A cAMP independent G s -mediated mechanism has been proposed for the stimulatory effects of A 2A R as well (4, 20) . Recently PKC⑀ has been shown to be important in the antiadrenergic effect of A 1 R (25) . Other recent studies (21, 22) have suggested that a significant component of the antiadrenergic effect of A 1 R is a result of protein phosphatase activation.
The individual effects of A 1 R and A 2A R on cardiac contractility at the cellular level have been fairly well characterized. However, their individual actions and the interaction between them in the intact heart remain topics of active interest. The main purpose of this study was to examine the interaction of A 1 R and A 2A R in the perfused murine heart subjected to ␤-adrenergic stimulation. The study also examined the actions of the A 1 R in the absence of A 2A R with the use of an A 2A R knockout (A 2A RKO) mouse heart and the effect of A 2A R activation in the absence of ␤-adrenergic stimulation. In addition, the influence of A 2A R on ischemic heart function was investigated.
MATERIALS AND METHODS

Experimental Animals
Six-to eight-week-old wild-type C57BL/6 male mice (WT) were purchased from Sprague-Dawley. A2ARKO mice were obtained from a colony maintained by our laboratory. The animals in this study were maintained and used in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and evaluated and approved according to the guidelines of the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School, Worcester, MA.
A 2ARKO Generation and Verification
The progenitors for the A2ARKO Ϫ/Ϫ mice were obtained as a generous gift from Dr. J. F. Chen of Boston University Medical Center (Boston, MA) and were generated as described previously by others (2) . The homozygous knockout animals used in the present study were offspring of heterozygous (ϩ/Ϫ) breeders. Animals were validated by using DNA isolated from tail tissue with the use of Qiagen DNEasy tissue kit. ISOlated DNA was amplified by PCR using Qiagen Taq DNA polymerase and primers: 1) AGC CAG GGG TTA CAT CTG TG, 2) TAC AGA CAG CCT CGA CAT GTG, 3) TCG GCC ATT GAA CAA GAT GG, and 4) GAG CAA GGT GAG ATG AGA GG. Primers 1 and 2 correspond to the WT A 2AR sequence, whereas primers 3 and 4 correspond to the A2ARKO sequence. Products of PCR were resolved by using 1% agarose gel electrophoresis in Tris-boric acid-EDTA buffer and visualized with ethidium bromide staining under UV light (WT, 180 bp; A 2ARKO, 330 bp). The agarose gels were used to verify the genotype of the mice (Fig. 1) .
Isolated Heart Preparation
Mice were euthanized by decapitation, and hearts were excised. After the excision, the hearts were rapidly rinsed in saline at room temperature, mounted on the perfusion apparatus, and perfused via the aorta with a physiological saline solution (37°C; PSS) containing (in mM) 118.4 NaCl, 4.7 KCl, 2.5 CaCl 2, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO 4, and 10 dextrose. The pH of the PSS was maintained at 7.4 by bubbling continuously with a 95% O2-5% CO2 gas mixture. The developed left ventricular pressure (LVP) was monitored by a pressure transducer and a canula tipped with a water-filled polyethylene balloon that was inserted through the mitral valve after a left atriotomy. Perfusion pressure was monitored by using a transducer connected to a sidearm of the perfusion cannula. The heart was paced with 3 V at 480 times/min via leads on the perfusion cannula and the pulmonary artery. All agents were delivered into the perfusion canula using infusion pumps (model 22, Harvard Apparatus, Holliston, MA) at the rate required (1.0% of perfusate flow rate) to achieve the final desired concentration in the perfusion fluid. The maximal rates of LVP development (ϩdP/dt max) and relaxation (ϪdP/dtmax) were determined by differentiation of the LVP signal. All data were recorded by using a model RS-3400 Gould polygraph (Chandler, AZ).
Protocols
General. For constant flow experiments, the flow rate was adjusted to achieve a LVP of at least 40 mmHg. Flow rates ranged from 2.5 to 2.9 ml/min. For constant pressure experiments, the perfusion pressure was held constant at 60 mmHg, and perfusate flow rate was determined volumetrically. Hearts were allowed to stabilize for at least 15 min before the initiation of experimental protocols. In both constant pressure and constant flow experiments, hearts failing to demonstrate a LVP of at least 40 mmHg on stabilization were excluded from further study. In experiments with ␤-adrenergic stimulation, isoproterenol (ISO) was infused for 30 s to achieve a final perfusate concentration of 10 Ϫ8 M. Adenosine receptor agonists and antagonists were infused to achieve a final perfusate concentration of 10 Ϫ7 M. Preliminary experiments conducted with the same concentration of ISO at infusion durations of 30 s, 1 min, and 2 min with 15 min washout did not indicate desensitization of ␤-adrenergic responsiveness with multiple ISO infusions (data not shown).
␤-Adrenergic-stimulated hearts. EFFECT OF A2AR ACTIVATION ON THE ANTIADRENERGIC EFFECT OF A1R. After stabilization, hearts were subjected to one 30-s ISO administration, and the peak contractile responses were recorded. After the hearts returned to steady state, infusion of the A1R agonist 2-chloro-N 6 -cyclopentyladenosine (CCPA) commenced. After 5 min of CCPA infusion, two additional ISO responses were elicited with a return to steady state between each administration. CCPA infusion was terminated after the second ISO response. CCPA and the A 2AR agonist 2-P(2-carboxyethyl)phenethyl-amino-5Ј-N-ethylcarboxyamidoadenosine (CGS-21680) were then administered together for 5 min, whereupon two more ISO responses were elicited while continuing the CCPA and CGS-21680 infusion. This protocol was conducted with both WT and A 2ARKO hearts. To confirm the response to CCPA as A 1R specific, in some preparations a combination of CCPA and the A1R antagonist 1,3-dipropyl-8-cyclopentyl-xanthine (DPCPX) was administered.
EFFECT OF A2AR ACTIVATION IN PRESENCE AND ABSENCE OF A1R
INHIBITION. In the first group, after stabilization, hearts were subjected to one 30-s ISO administration, and contractile responses were recorded. On return to baseline, the A 2AR agonist CGS-21680 was administered for 5 min, and three 30-s ISO responses were elicited, allowing a return to baseline between stimulations.
In the second group, after stabilization, hearts were subjected to one 30-s ISO administration, and contractile responses were recorded. On return to baseline, the A 1R antagonist DPCPX was administered for 5 min, and two 30-s ISO responses were elicited, allowing a return to baseline after each stimulation. Subsequently, a combination of DPCPX and A 2AR agonist CGS-21680 was administered for 5 min, and two 30-s ISO responses were elicited as before.
Reduced flow experiments. For flow reduction experiments, the hearts were initially perfused at a rate of 3.0 ml/min. The response to a 1 ml/min flow rate decrease was examined under several experimental conditions. These protocols are depicted in Fig. 7 .
EFFECT OF A2AR ACTIVATION ON CONTRACTILE RESPONSE TO FLOW REDUCTION. After stabilization, hearts were subjected to three periods of flow reduction, each of 1 min duration separated by periods of normal perfusion (3 ml/min) for ϳ3 min, allowing a return to baseline contractility ( 
EFFECT OF CGS-LIKE DECREASE IN PERFUSION PRESSURE ON THE
CONTRACTILE RESPONSE TO FLOW REDUCTION. The contractile effects of CGS-21680 were further differentiated from the vasodilatory effects of CGS-21680. The response to a 1-ml flow decrease was examined while using a manual reduction in flow to achieve a decrease in perfusion pressure comparable to that occurring in response to CGS-21680 administration. After initial stabilization, the heart was subjected to three 1-min periods of flow reduction separated by periods of normal perfusion (3.0 ml/min) for ϳ3 min, allowing a return of contractile function to preflow reduction levels. The flow was then reduced to the extent required to produce the same decrease in perfusion pressure as observed with CGS-21680 administration (a decrease of 40 -45 mmHg). After stabilization at this new baseline, three more periods of an additional flow decrease of 1 ml/min were administered. Changes in flow with expected changes in perfusion pressure are depicted in Fig. 7 , D and E, respectively. 
Data and Statistical Analysis
When multiple ISO administrations or flow reductions were used, the responses were averaged. Data are presented as means Ϯ SE. Data were analyzed with the use of Prism (GraphPad Software, San Diego, CA) software. Additional statistical analysis was done by using StatMost (Dataxiom, Los Angeles, CA) software. Data were analyzed using one-way ANOVA, Student-Newman-Keuls multiple comparison test, and two-tailed t-test where appropriate. Values were taken to indicate a statistically significant difference at P Ͻ 0.05.
Materials
ISO was dissolved in 0.1% sodium metabisulfite and diluted to the infusion concentration of 10 Ϫ6 M with MilliQ-treated water. CCPA, CGS-21680, ZM-241385, and DPCPX were prepared as 10 mM stock solutions in 100% DMSO and diluted with water to 10 Ϫ5 M that was used for infusion into the perfusion fluid. The resultant perfusion fluid DMSO concentration was not Ͼ0.05%. Buffer salts were purchased from Fisher Scientific (Fairlawn, NJ). ISO and adenosine receptor agents CCPA, DPCPX, and CGS-21680 were obtained from Sigma-RBI (St. Louis, MO), and the A2AR antagonist ZM-241385 was purchased from Tocris (Ellisville, MO). Custom primers and DNA reference ladder were acquired from Invitrogen (Carlsbad, CA). Precast 1% agarose minigels with ethidium bromide were obtained from Bio-Rad (Hercules, CA). Qiagen DNEasy tissue kit and Qiagen Taq DNA polymerase Core kit were purchased from Qiagen (Valencia, CA).
RESULTS
␤-Adrenergic-Stimulated Hearts
Effects of A 1 R and A 2A R activation in ␤-adrenergic-stimulated hearts. In constant flow-perfused WT hearts, the administration of the A 1 R agonist CCPA reduced the contractile response to ISO stimulation (Fig. 2) . Although CCPA reduced the ISO-induced increase in LVP by 15%, this reduction was not statistically significant ( Fig. 2A) . However, the A 1 R agonist significantly attenuated the ISO-induced increase in ϩdP/dt max by 22% (Fig. 2B) . The ISO responses in the presence of CGS-21680 (reductions of 23% and 28% for LVP and ϩdP/dt max , respectively) remained significantly below those observed in the presence of ISO alone. These values were not significantly different from the CCPA plus ISO responses.
Experiments were repeated with constant perfusion pressure rather than constant flow (Fig. 3) . CGS-21680 administration resulted in an attenuation of the antiadrenergic effect of A 1 R. With CCPA treatment the values for LVP (Fig. 3A) and ϩdP/dt max ( Fig. 3B ) with ISO stimulation were each reduced by 27%. The antiadrenergic effect of CCPA was fully reversed by an addition of the A 1 R antagonist DPCPX (data not shown). CGS-21680 attenuated the antiadrenergic effect of CCPA. In the presence of CGS-21680, CCPA only reduced the ISOinduced LVP and ϩdP/dt max responses by 12% and 18%, respectively. These values were significantly different from ISO responses observed with CCPA in the absence of CGS-21680. It is concluded that the absence of a CGS-21680 effect in the constant flow preparation (Fig. 2) resulted from the possible influence of a decrease in perfusion pressure resulting from A 2A R-induced vasodilation. Although CCPA had no effect on perfusion pressure, CGS-21680 administration resulted in a 35% decrease in perfusion pressure (from 100 mmHg) compared with values for the control and CCPA. The data were further examined as a percentage increase in ϩdP/ dt max in response to ISO stimulation (Fig. 4) . With data expressed in this manner, attenuation of the antiadrenergic effect of CCPA by CGS-21680 was observed for both constant flow and constant pressure preparations. CCPA reduced the ISO response by 34% and 53% for constant pressure and flow, respectively. However, the ISO responses were decreased only by 10% and 35%, respectively, in the presence of both CGS-21680 and CCPA.
Effects of A 1 R activation in WT versus A 2A RKO hearts. The response to A 1 R activation, along with ␤-adrenergic stimulation in the absence and presence of A 2A R stimulation, was compared between WT and A 2A RKO hearts (Fig. 5) . In the WT heart, ISO stimulation resulted in a 244% increase in ϩdP/dt max . In the presence of CCPA, ISO only increased ϩdP/dt max by 123%. CGS-21680 attenuated this antiadrenegic action, as evidenced by an ISOϩCCPA response of 151%.
In the A 2A RKO heart, ISO stimulation resulted in a 253% increase in ϩdP/dt max . In the presence of CCPA, ISO only increased ϩdP/dt max by 169%. CGS-21680 in the presence of CCPA resulted in an ISO response of only 125%. The ISOinduced increase in ϩdP/dt max after administration of both CCPA and CGS-21680 was not significantly different between A 2A RKO and WT hearts. (Fig. 2) and 5 experiments using constant pressure (Fig. 3) perfusion. *Statistically significant difference from respective control (ISO) value; §statistically significant difference from respective CCPA value. 
Direct versus indirect effect of A 2A R in WT hearts.
To estimate the extent of the A 2A R effect achieved by a direct increase in contractility, as opposed to its indirect effect through the inhibition of A 1 R, A 2A R activation in the presence and absence of A 1 R inhibition was examined (Fig. 6) . ISO alone resulted in a 308% increase in ϩdP/dt max (Fig. 6A) . In the presence of CGS-21680, this response was increased to 490%, reflecting a 182 percentage-point (⌬1) increase from ISO alone. This response is attributable to both the direct and indirect effects of the A 2A R. In the presence of an A 1 R blockade by DPCPX, CGS-21680 resulted in an increase of only 67 percentage points (⌬2) above that of the ISO response (Fig. 6B) . It is assumed that the increase in the ISO response with CGS-21680 in the presence of A 1 R blockade by DPCPX is due to the direct effect of A 2A R on contractility and that the direct and indirect effects of CGS-21680 are independent and additive. The indirect effect of A 2A R acting on the A 1 R can be estimated by subtracting the direct effect from the value representing both direct and indirect influences (⌬3, Fig.   6C ). Determined in this manner, the indirect effect of the A 2A R through the inhibition of A 1 R is ϳ63% of the total A 2A R effect.
Reduced Flow Experiments
In the absence of ␤-adrenergic stimulation, the contractile response to A 2A R activation in an intact heart is relatively small (5-10%) compared with that at baseline (26) . Furthermore, contractile activity is affected by the fall in perfusion pressure inherent with A 2A R-induced vasodilation in the constant flow preparation. As described in MATERIALS AND METHODS, flow reduction experiments were designed to investigate the effects of A 2A R activation in the absence of ␤-adrenergic stimulation (Fig. 7, A-C) . Additional experiments were designed to examine the effect of the perfusion pressure decrease that occurs with CGS-21680-induced vasodilation on contractile function (Fig. 7, D and E) . A 3.0 ml/min rate of flow was chosen as baseline to permit maximal oxygenation and con- tractile function without the risk of edema that is caused by higher flow rates. A 2A R effect on contractile function with reduced flow. In the absence of CGS-21680, a flow reduction of 1 ml/min (RF1) resulted in a 32% decrease in perfusion pressure (Fig. 8A) , which in turn led to significant 33%, 30%, and 43% decreases in LVP, ϩdP/dt max , and ϪdP/dt max , respectively, compared with control values (Fig. 8, B and C) . In the presence of CGS-21680, a vasodilation elicited a drop in perfusion pressure of 45 mmHg. This represents a 50% decrease from the level observed in the absence of the A 2A R agonist. This value was significantly lower than that observed after the flow decrease (RF1) in the absence of CGS-21680. In the presence of CGS-21680, the LVP and ϮdP/dt max were significantly decreased from control values. However, these contractile parameters with CGS-21680 were significantly higher than those seen during RF1 without CGS-21680, despite the lower perfusion pressure. In the presence of CGS-21680, a 1 ml/min flow decrease resulted in a 32% decrease in perfusion pressure compared with the A 2A R agonist alone (Fig. 8A) . This reduction in perfusion pressure was associated with decreases of 27% in LVP (Fig. 8B) , 23% in ϩdP/dt max , and 39% in ϪdP/dt max (Fig. 8C) .
To verify the CGS-21680 response as A 2A R specific, experiments were repeated by using the A 2A R antagonist ZM-241385. The previously observed effects of CGS-21680 were blocked by ZM-241385 (data not shown). These results indicate that the enhanced contractility observed, despite a decrease in perfusion pressure, is A 2A R specific.
Effect of A 2A R-comparable perfusion pressure reduction on contractile function. Experiments were conducted to ascertain whether the changes in contractile response to flow reduction were due to the effect of CGS-21680 on contractility or as a result of the A 2A R agonist-induced decrease in perfusion pressure. A protocol was designed with a similar sequence of flow Fig. 9 . Effect of a CGS-like perfusion pressure drop (RF2) in conjunction with a brief flow reduction (RF1) on perfusion pressure (A), LVP (B), and ϮdP/ dtmax (C) in the constant flow-perfused murine heart. Data are means Ϯ SE for 6 experiments. *Statistically significant difference from control value; **statistically significant difference from RF2 value alone. decreases (RF1). However, instead of CGS-21680 administration, the flow was manually reduced (RF2) to the extent required to simulate the decrease in perfusion pressure of 40 -45 mmHg that occurs with CGS-21680 (Fig. 8) . The changes observed in LVP and ϮdP/dt max correlated closely with the decreases in perfusion pressure (Fig. 9) . The flow reduction RF2 decreased perfusion pressure, LVP, ϩdP/dt max , and ϪdP/dt max by 36%, 32%, 32%, and 46%, respectively. The decreases in these four parameters showed no significant differences from those observed during RF1.
Further analysis of the data presented in Figs. 8 and 9 reveals that the contractile depression occurring with RF1 is attenuated by CGS-21680. In the absence of CGS-21680, RF1 resulted in decreases of 870 (36%) and 763 mmHg/s (43%) in ϩdP/dt max and ϪdP/dt max , respectively (Fig. 8C) . However, after CGS-21680 administration RF1 resulted in decreases of 559 (23%) and 535 mmHg/s (38%) in ϩdP/dt max and ϪdP/dt max , respectively. A significant decrease in response to RF1 in the presence of CGS-21680 may also be observed when examining the percentage decrease in ϮdP/dt max , resulting from RF1 (Fig.  10A) . The decreases (in %) presented in Fig. 10 are the means of the appropriate differences obtained from Figs. 8 and 9 . Attenuation of the contractile response to RF1 observed in the presence of CGS-21680 (Fig. 10A) did not occur in preparations using a manual flow reduction to simulate CGS-21680-induced decrease in perfusion pressure (Fig. 10B) . The attenuation of RF1 contractile depression with CGS-21680 was prevented by the A 2A R antagonist ZM-241385 (Fig. 10C) .
DISCUSSION
A 2A R and A 1 R Activation in Presence of ␤-Adrenergic Stimulation
The main finding of this study is that A 2A R increases the contractile performance of the myocardium through both direct and indirect mechanisms in the ␤-adrenergic-stimulated mouse heart. The actions of A 2A R also support myocardial contractility during reduced flow (low-flow ischemia). These results extend the previously reported observations that the A 2A R can increase contractility in intact hearts and cardiomyocytes that are obtained from rats (4, 19, 26, 34) . The A 1 R and A 2A R interaction has also been reported previously in the rat heart (28) and isolated rat cardiomyocytes (34) , although the exact mechanism by which this occurs remains unknown. The antiadrenergic action of A 1 R is thought to be mediated through multiple signaling mechanisms involving a decrease in adenylyl cyclase activity (18) , reduction in calcium transients (12, 28) , and increased PKC⑀ translocation (25) . The inhibition of the A 1 R effect by the A 2A R may occur by a modulation of any of these processes. Postulated mechanisms for the effects of the A 2A R have included an activation of adenylyl cyclase (19) , calcium-dependent and -independent mechanisms (4, 7, 33) , as well as cAMP-independent mechanisms (4, 20) . Based on the data presented, the effects of the A 2A R can be considered as both direct and indirect. Direct effects involve the improvement of contractile performance through positive effects, such as an enhanced activation of adenylyl cyclase, whereas indirect effects involve the inhibition of the antiadrenergic effects of A 1 R. The direct effects of A 2A R activation in the intact heart can be observed independently of ␤-adrenergic stimulation as described by Monahan et al. (26) . However, the effect of A 2A R activation becomes more pronounced when examined in the presence of ␤-adrenergic stimulation.
In both constant flow and constant pressure preparations, A 2A R stimulation was observed to attenuate the antiadrenergic effects of A 1 R activation. The direct increase in contractile performance observed with the activation of the A 2A R was consistent with previous reports (26) in which rat hearts were used. Interestingly, in the constant perfusion pressure preparation, A 2A R activation appeared to have a greater effect than with constant flow. Although CGS-21680 significantly attenuated the effects of CCPA in both constant flow and constant pressure preparations, the ϩdP/dt max returned to control levels in the constant pressure preparation but remained significantly below control level in the constant flow preparation after treatment with CGS-21680 (Fig. 4) . This observation is likely due to the increased perfusion flow and vascular filling seen with constant pressure perfusion. Increased regional tissue distension as a result of increased vascular filling may result in ventricular myocytes experiencing enhanced preload conditions (Water hose/Gregg effect; 16, 30) .
With respect to the attenuation of the A 1 R effect by A 2A R, the findings of the present study confirm those reported by Norton et al. (28) in the rat heart. It is possible, however, to further delineate the functional aspect of the A 2A R effect into direct and indirect components. To estimate the extent to which each of these mechanisms of A 2A R action occurs in the adrenergic-stimulated mouse heart, the contractile response to CGS-21680 stimulation of the A 2A R was compared in the presence and absence of A 1 R inhibition. The ISO response in the presence of CGS-21680 is presumed to be affected by both mechanisms in an additive fashion, i.e., A 2A R is able to both inhibit the manifestation of A 1 R effects and increase contractility directly. The direct action of A 2A R can be revealed by pretreating the heart with the A 1 R antagonist DPCPX before A 2A R stimulation. The resulting increase in the contractile response to ISO in this case is due to the direct effect of the A 2A R on contractility. The observed increase in the ISO response with CGS-21680 was reduced after pretreatment with DPCPX (Fig. 6) . The additional increase in the ISO response was approximately a third of the response seen when CGS-21680 was administered without prior A 1 R inhibition (⌬1 vs. ⌬2; Fig. 6 ). These calculations suggest that a major part of the A 2A R effect is mediated through the inhibition of the A 1 R (indirect effect), as opposed to its direct effect on contractility. This conclusion is consistent with the observation that A 2A R activation only has a minor effect on contractility (5-10%) in the absence of adrenergic stimulation. In the presence of adrenergic stimulation where the A 1 R plays a significant role in attenuating the adrenergic response, the A 2A R exerts a more profound inhibitory effect on the antiadrenergic action of A 1 R. Thus the interaction of the A 2A R and the A 1 R is of greater importance in the adrenergic-stimulated heart.
A 1 R and A 2A R Stimulation Response: Comparing Knockout and WT Hearts
There were two findings of interest when comparing the responses of A 1 R and A 2A R activation in WT and A 2A RKO hearts. First, the observed response to A 1 R activation was greater in the WT than in the A 2A RKO hearts (Fig. 5) . The ISO responses observed were not markedly different between WT and A 2A RKO hearts, whereas there was approximately a 50 percentage point difference between the average ISO response levels in the presence of CCPA. These findings conflict with previous reports indicating that in a WT rat heart, the inhibition of A 2A R with ZM-241385 increased the antiadrenergic effects of A 1 R activation (28) . The absence of the A 2A R in the A 2A RKO heart should result in a situation similar to that where the A 2A Rs are inhibited pharmacologically. It would be expected that the A 2A RKO would be more responsive to the antiadrenergic effect of A 1 R. However, the opposite was observed in the present experiments. It is possible that this is due to a modification of A 1 R signaling in the A 2A RKO. However, the study of vascular smooth muscle responses to adenosine analogs in the A 2A RKO mouse suggested no adaptations (29) . The reason for the presently observed enhancement of the A 1 R response in A 2A RKO hearts remains to be explored.
The second notable difference between the WT and A 2A RKO hearts was the response to the CGS-21680 and CCPA combination. In the WT hearts, CGS-21680 produced an increase in contractile response to ISO from that observed in the presence of CCPA, as expected. However, in the A 2A RKO hearts, there was a further decrease in ISO contractile response after treatment with CCPA and CGS-21680 together. A possible explanation is an interaction between CGS-21680 and the A 1 R. A binding of CGS-21680 to tissues in an A 1 R-dependent manner has been reported in the mouse brain (15, 23) . The exact nature of this interaction between CGS-21680 and A 1 R remains unknown. The observed decrease in the ISO contractile response seen with CGS-21680 beyond that with CCPA alone may occur in the A 2A RKO hearts, because CCPA together with CGS-21680 activates the A 1 R to a greater extent.
A 2A R Supports Myocardial Contractility With Low-Flow Ischemia
To study the importance of A 2A R activation in providing contractile support in a nonadrenergic-stimulated heart and the role of vasodilation in the contractile effects of A 2A R activation, an experimental protocol was used where the response to brief periods of low-flow ischemia was examined. The effect of A 2A R on contractility in the absence of adrenergic stimulation is small. In the current protocol, where a decrease in flow rather than adrenergic stimulation was applied, it was possible to examine the effect of A 2A R activation on contractility even in the absence of adrenergic stimulation. There were two main findings in this series of experiments. First, A 2A R activation resulted in a higher level of observed contractile performance at a given perfusion pressure. After the administration of CGS-21680, vasodilation resulted in a perfusion pressure significantly lower than that observed with the l-ml flow decrease (RF1, Fig. 8A ). Despite this result, the observed LVP and ϮdP/dt max were both higher than that observed after RF1 in the absence of CGS-21680. This indicates that in the presence of A 2A R stimulation, myocardial contractility is enhanced as evidenced by the increased LVP and ϮdP/dt max at a given perfusion pressure. This effect was fully reversible with the A 2A R antagonist ZM-241385 and thus was attributable to A 2A R.
The second observation of interest was that the actual decrease in contractility observed during the administered periods of low-flow ischemia (RF1) was significantly less in the presence of A 2A R stimulation with CGS-21680. This difference was most clearly visible with respect to ϮdP/dt max (Fig. 10) . To determine whether this observation was due to A 2A R contractile effects, as opposed to the result of the decreased perfusion pressure resulting from CGS-21680-induced vasodilation, another series of experiments used a manual decrease in flow (RF2, Fig. 9 ) to simulate the decrease in perfusion pressure caused by CGS-21680 administration. This manual perfusion pressure decrease did not attenuate the extent of contractile function reduction seen with flow drop RF1. In fact, the attenuation of response to flow reduction was only seen with CGS-21680 and was prevented by the A 2A R antagonist ZM-24138.
In summary, this study has found that the A 2A R enhances the contractile response to ␤-adrenergic stimulation in the murine heart directly through an effect on contractility and indirectly by an attenuation of the antiadrenergic actions of the A 1 R. In addition, A 2A R activation supports contractile function during low-flow ischemia, resulting in an increased contractile function at the given reduced perfusion pressure.
